search
Back to results

Therapeutic Zinc in Childhood Pneumonia

Primary Purpose

Pneumonia

Status
Completed
Phase
Phase 2
Locations
Nepal
Study Type
Interventional
Intervention
Zinc (zinc sulphate)
Placebo
Sponsored by
Centre For International Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pneumonia focused on measuring Child, severe pneumonia, Zinc, Nepal, therapeutic

Eligibility Criteria

2 Months - 35 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Children aged 2- 35 months with a history of cough (duration <14days) and difficult breathing of </= 72hours' duration, with lower chest indrawing. Availability of informed consent. Exclusion Criteria: Children with severe wasting (<70% NCHS median weight for height) Severe anemia (hemoglobin <7 gm/dl.) Presence of heart disease with or without signs of cardiac failure. Child with a chronic cough (lasting for ≥14 days) Documented tuberculosis with ongoing treatment. Associated other severe diseases that require special care or surgical intervention. Children with concomitant diarrhea with some/severe dehydration Children with a history of recurrent wheezing Children enrolled in the study within the last 6 months of this visit

Sites / Locations

  • Kanti Children Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Zinc

Placebo

Arm Description

Zinc sulphate 10 or 20 mg per day

Placebo

Outcomes

Primary Outcome Measures

Time to cessation of severe pneumonia
The period starting from enrolment to the beginning of a 24-hour consecutive period of absence of lower chest indrawing, of hypoxia and of any danger signs.

Secondary Outcome Measures

Full Information

First Posted
November 10, 2005
Last Updated
October 2, 2009
Sponsor
Centre For International Health
Collaborators
Tribhuvan University, Nepal, Statens Serum Institut, All India Institute of Medical Sciences, New Delhi, Institut de Recherche pour le Developpement, Society for Applied Studies
search

1. Study Identification

Unique Protocol Identification Number
NCT00252304
Brief Title
Therapeutic Zinc in Childhood Pneumonia
Official Title
Efficacy of Zinc as Adjuvant Therapy in the Treatment of Severe Pneumonia in Nepalese Children at the Kanti Children's Hospital
Study Type
Interventional

2. Study Status

Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Centre For International Health
Collaborators
Tribhuvan University, Nepal, Statens Serum Institut, All India Institute of Medical Sciences, New Delhi, Institut de Recherche pour le Developpement, Society for Applied Studies

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to assess whether zinc given as adjuvant therapy to standard antibiotic treatment in children hospitalized for severe pneumonia reduces the duration of the severe illness and risk of treatment failure. A randomized double blind placebo controlled clinical trial will be conducted at the Kanti Hospital.
Detailed Description
Nepal has an under-five mortality rate of 91/1000 live births. Pneumonia, one of the major killers accounts for the death of 25,000 - 35,000 Nepalese children every year. It is estimated that, on an average, of 1000 children <5 years of age that visit health facilities, 90 have pneumonia of which 4.2 have severe pneumonia. At the Kanti Children's Hospital, respiratory diseases are the most frequent reason for admission and the second most frequent cause of child death Zinc, an important micronutrient, is crucial for the normal function of the immune system as well as the integrity of the respiratory epithelium. Zinc deficiency is associated with an increased incidence and severity of diarrhea and respiratory tract infections. The preventive effect of zinc on diarrheal and respiratory illness has been well documented. Early in an infection zinc is shifted into the liver from the plasma, bone, skin and intestines. For a child with initial low zinc levels, even relatively trivial infections may cause entry into the vicious cycle of reduced plasma zinc and increased infection severity. Administration of zinc during the acute illness may help in reducing the severity of illness. The therapeutic effect of zinc in acute diarrhea has been well documented. In a study conducted at Bhaktapur, Nepal, in children 6 to 36 months of age, supplementation with zinc was found to be highly effective in the treatment of acute diarrhea. The Kanti Children's Hospital in Kathmandu serves as a general and referral hospital for children from all parts of the country. Approximately 25% of all admissions to this hospital are due to pneumonia. Being the only well recognized children's hospital, there is always a constraint for available beds for children presenting with pneumonia. Zinc as an adjuvant to standard treatment of pneumonia with antimicrobials was found to hasten recovery from severe pneumonia in children less than 2 years of age in Bangladesh . If we were to conduct a similar study and prove that zinc does in fact help to shorten the duration of illness in children with severe pneumonia, it would go a long way in contributing to improve case management.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia
Keywords
Child, severe pneumonia, Zinc, Nepal, therapeutic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
641 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Zinc
Arm Type
Experimental
Arm Description
Zinc sulphate 10 or 20 mg per day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Zinc (zinc sulphate)
Other Intervention Name(s)
Produced by Nutriset, Malaunay, France
Intervention Description
Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Produced by Nutriset, Malaunay, France
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Time to cessation of severe pneumonia
Time Frame
Within 2 weeks after enrollment
Title
The period starting from enrolment to the beginning of a 24-hour consecutive period of absence of lower chest indrawing, of hypoxia and of any danger signs.
Time Frame
Recovery from pneumonia within 2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
35 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 2- 35 months with a history of cough (duration <14days) and difficult breathing of </= 72hours' duration, with lower chest indrawing. Availability of informed consent. Exclusion Criteria: Children with severe wasting (<70% NCHS median weight for height) Severe anemia (hemoglobin <7 gm/dl.) Presence of heart disease with or without signs of cardiac failure. Child with a chronic cough (lasting for ≥14 days) Documented tuberculosis with ongoing treatment. Associated other severe diseases that require special care or surgical intervention. Children with concomitant diarrhea with some/severe dehydration Children with a history of recurrent wheezing Children enrolled in the study within the last 6 months of this visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sudha Basnet, MD
Organizational Affiliation
Department of Child Health, Institute of Medicine, Tribhuwan University, Katmandu, Nepal
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tor A Strand, MD, PhD
Organizational Affiliation
Centre For International Health
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Halvor Sommerfelt, MD, PhD
Organizational Affiliation
Centre For International Health
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Nita Bhandari, MBBS, PhD
Organizational Affiliation
Centre For International Health
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Prakash S Shrestha, MD
Organizational Affiliation
Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj:
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ramesh K Adhikari, MD
Organizational Affiliation
Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj:
Official's Role
Study Chair
Facility Information:
Facility Name
Kanti Children Hospital
City
Kathmandu
Country
Nepal

12. IPD Sharing Statement

Citations:
Citation
Nepal Demographic and Health Survey, 2001
Results Reference
background
Citation
Nepal Ministry of Health, Department of Health Services Annual Report 2000- 2001, Kathmandu
Results Reference
background
PubMed Identifier
9701160
Citation
Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998 Aug;68(2 Suppl):447S-463S. doi: 10.1093/ajcn/68.2.447S.
Results Reference
background
PubMed Identifier
9701154
Citation
Bahl R, Bhandari N, Hambidge KM, Bhan MK. Plasma zinc as a predictor of diarrheal and respiratory morbidity in children in an urban slum setting. Am J Clin Nutr. 1998 Aug;68(2 Suppl):414S-417S. doi: 10.1093/ajcn/68.2.414S.
Results Reference
background
PubMed Identifier
10586170
Citation
Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr. 1999 Dec;135(6):689-97. doi: 10.1016/s0022-3476(99)70086-7.
Results Reference
background
PubMed Identifier
12042580
Citation
Bhandari N, Bahl R, Taneja S, Strand T, Molbak K, Ulvik RJ, Sommerfelt H, Bhan MK. Substantial reduction in severe diarrheal morbidity by daily zinc supplementation in young north Indian children. Pediatrics. 2002 Jun;109(6):e86. doi: 10.1542/peds.109.6.e86.
Results Reference
background
PubMed Identifier
9701156
Citation
Brown KH. Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. Am J Clin Nutr. 1998 Aug;68(2 Suppl):425S-429S. doi: 10.1093/ajcn/68.2.425S.
Results Reference
background
Citation
Beisel WR. Zinc metabolism in infection. In: Brewer GJ, Prasad AS, eds. Zinc metabolism: current aspects in health and disease. New York: Alan R Liss, 1977: 973-977
Results Reference
background
PubMed Identifier
2458983
Citation
Cousins RJ, Leinart AS. Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin 1. FASEB J. 1988 Oct;2(13):2884-90. doi: 10.1096/fasebj.2.13.2458983.
Results Reference
background
PubMed Identifier
12654820
Citation
Strand TA, Hollingshead SK, Julshamn K, Briles DE, Blomberg B, Sommerfelt H. Effects of zinc deficiency and pneumococcal surface protein a immunization on zinc status and the risk of severe infection in mice. Infect Immun. 2003 Apr;71(4):2009-13. doi: 10.1128/IAI.71.4.2009-2013.2003.
Results Reference
background
PubMed Identifier
11101480
Citation
Bhutta ZA, Bird SM, Black RE, Brown KH, Gardner JM, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am J Clin Nutr. 2000 Dec;72(6):1516-22. doi: 10.1093/ajcn/72.6.1516.
Results Reference
background
PubMed Identifier
11986453
Citation
Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, Ulvik RJ, Molbak K, Bhan MK, Sommerfelt H. Effectiveness and efficacy of zinc for the treatment of acute diarrhea in young children. Pediatrics. 2002 May;109(5):898-903. doi: 10.1542/peds.109.5.898.
Results Reference
background
PubMed Identifier
15158629
Citation
Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. Lancet. 2004 May 22;363(9422):1683-8. doi: 10.1016/S0140-6736(04)16252-1.
Results Reference
background
PubMed Identifier
28678771
Citation
Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, Valentiner-Branth P, Strand TA. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017 Dec;82(6):986-993. doi: 10.1038/pr.2017.71. Epub 2017 Aug 16.
Results Reference
derived
PubMed Identifier
22392179
Citation
Basnet S, Shrestha PS, Sharma A, Mathisen M, Prasai R, Bhandari N, Adhikari RK, Sommerfelt H, Valentiner-Branth P, Strand TA; Zinc Severe Pneumonia Study Group. A randomized controlled trial of zinc as adjuvant therapy for severe pneumonia in young children. Pediatrics. 2012 Apr;129(4):701-8. doi: 10.1542/peds.2010-3091. Epub 2012 Mar 5.
Results Reference
derived

Learn more about this trial

Therapeutic Zinc in Childhood Pneumonia

We'll reach out to this number within 24 hrs